| pubmed-article:11720857 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11720857 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:11720857 | lifeskim:mentions | umls-concept:C0330390 | lld:lifeskim |
| pubmed-article:11720857 | lifeskim:mentions | umls-concept:C0034783 | lld:lifeskim |
| pubmed-article:11720857 | lifeskim:mentions | umls-concept:C0243192 | lld:lifeskim |
| pubmed-article:11720857 | lifeskim:mentions | umls-concept:C0041942 | lld:lifeskim |
| pubmed-article:11720857 | lifeskim:mentions | umls-concept:C1434721 | lld:lifeskim |
| pubmed-article:11720857 | pubmed:issue | 24 | lld:pubmed |
| pubmed-article:11720857 | pubmed:dateCreated | 2001-11-26 | lld:pubmed |
| pubmed-article:11720857 | pubmed:abstractText | The preparation and structure-activity relationships (SARs) of potent agonists of the human beta(3)-adrenergic receptor (AR) derived from a 4-aminopiperidine scaffold are described. Examples combine human beta(3)-AR potency with selectivity over human beta(1)-AR and/or human beta(2)-AR agonism. Compound 29s was identified as a potent (EC(50)=1nM) and selective (greater than 400-fold over beta(1)- with no beta(2)-AR agonism) full beta(3)-AR agonist with in vivo activity in a transgenic mouse model of thermogenesis. | lld:pubmed |
| pubmed-article:11720857 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11720857 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11720857 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11720857 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11720857 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11720857 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11720857 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11720857 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11720857 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:11720857 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:11720857 | pubmed:author | pubmed-author:HamRR | lld:pubmed |
| pubmed-article:11720857 | pubmed:author | pubmed-author:AshwellM AMA | lld:pubmed |
| pubmed-article:11720857 | pubmed:author | pubmed-author:TilleyGG | lld:pubmed |
| pubmed-article:11720857 | pubmed:author | pubmed-author:LargisEE | lld:pubmed |
| pubmed-article:11720857 | pubmed:author | pubmed-author:MulveyRR | lld:pubmed |
| pubmed-article:11720857 | pubmed:author | pubmed-author:SolvibileW... | lld:pubmed |
| pubmed-article:11720857 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11720857 | pubmed:day | 17 | lld:pubmed |
| pubmed-article:11720857 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:11720857 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11720857 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11720857 | pubmed:pagination | 3123-7 | lld:pubmed |
| pubmed-article:11720857 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:11720857 | pubmed:meshHeading | pubmed-meshheading:11720857... | lld:pubmed |
| pubmed-article:11720857 | pubmed:meshHeading | pubmed-meshheading:11720857... | lld:pubmed |
| pubmed-article:11720857 | pubmed:meshHeading | pubmed-meshheading:11720857... | lld:pubmed |
| pubmed-article:11720857 | pubmed:meshHeading | pubmed-meshheading:11720857... | lld:pubmed |
| pubmed-article:11720857 | pubmed:meshHeading | pubmed-meshheading:11720857... | lld:pubmed |
| pubmed-article:11720857 | pubmed:meshHeading | pubmed-meshheading:11720857... | lld:pubmed |
| pubmed-article:11720857 | pubmed:meshHeading | pubmed-meshheading:11720857... | lld:pubmed |
| pubmed-article:11720857 | pubmed:meshHeading | pubmed-meshheading:11720857... | lld:pubmed |
| pubmed-article:11720857 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11720857 | pubmed:articleTitle | 4-Aminopiperidine ureas as potent selective agonists of the human beta(3)-adrenergic receptor. | lld:pubmed |
| pubmed-article:11720857 | pubmed:affiliation | Chemical Sciences, Wyeth-Ayerst Research, PO Box CN-8000, USA. mashwell@arqule.com | lld:pubmed |
| pubmed-article:11720857 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:11720857 | lld:chembl |
